PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
P/E ratio for PepGen Inc. (PEPG)
P/E ratio as of 2023: -2.06
According to PepGen Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.06. At the end of 2022 the company had a P/E ratio of -4.59.
P/E ratio history for PepGen Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.06 |
| 2022 | -4.59 |
| 2021 | -10.58 |
| 2020 | -153.45 |
| 2019 | -214.45 |